From: A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
Parameters
Fingolimod-treatment group
IFNβ-treatment group
Age (mean ± SD)
39.08 ± 7.63
36.83 ± 7.24
Sex ratio (Female/male)
24/6
18/7
Disease duration
8.20 ± 3.42
8.77 ± 2.5
EDSS (mean ± SD)
4.92 ± 0.73
4.52 ± 1.09